These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 21609230)
41. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis. Suman VJ; Dueck A; Sargent DJ Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764 [No Abstract] [Full Text] [Related]
42. Overview of progress in the epidemiology of age-related macular degeneration. Klein R Ophthalmic Epidemiol; 2007; 14(4):184-7. PubMed ID: 17896295 [TBL] [Abstract][Full Text] [Related]
43. Endpoints for assessing drug activity in clinical trials. Pazdur R Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634 [TBL] [Abstract][Full Text] [Related]
44. Transplantation of the RPE in AMD. Binder S; Stanzel BV; Krebs I; Glittenberg C Prog Retin Eye Res; 2007 Sep; 26(5):516-54. PubMed ID: 17532250 [TBL] [Abstract][Full Text] [Related]
45. An update on the genetics of age-related macular degeneration. Scholl HP; Fleckenstein M; Charbel Issa P; Keilhauer C; Holz FG; Weber BH Mol Vis; 2007 Feb; 13():196-205. PubMed ID: 17327825 [TBL] [Abstract][Full Text] [Related]
46. Polymorphisms in C2, CFB and C3 are associated with progression to advanced age related macular degeneration associated with visual loss. Francis PJ; Hamon SC; Ott J; Weleber RG; Klein ML J Med Genet; 2009 May; 46(5):300-7. PubMed ID: 19015224 [TBL] [Abstract][Full Text] [Related]
47. The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases. Lonn E Pharmacoepidemiol Drug Saf; 2001; 10(6):497-508. PubMed ID: 11828831 [TBL] [Abstract][Full Text] [Related]
50. Visual Function Endpoints to Enable Dry AMD Clinical Trials. Lesmes LA; Jackson ML; Bex P Drug Discov Today Ther Strateg; 2013; 10(1):e43-e50. PubMed ID: 32863843 [TBL] [Abstract][Full Text] [Related]
51. The roadmap to geographic atrophy treatment: A journey of trials and promise. Trivizki O; Loewenstein A; Zur D Acta Ophthalmol; 2023 Dec; 101(8):891-895. PubMed ID: 37933605 [TBL] [Abstract][Full Text] [Related]
52. What's the difference between wet and dry macular degeneration? Johns Hopkins Med Lett Health After 50; 2012 Feb; 23(12):7. PubMed ID: 22397006 [No Abstract] [Full Text] [Related]
53. Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases. Bocci V; Zanardia I; Valacchi G; Borrelli E; Travagli V Cardiovasc Hematol Disord Drug Targets; 2015; 15(2):127-38. PubMed ID: 26126818 [TBL] [Abstract][Full Text] [Related]
54. Potential role of lampalizumab for treatment of geographic atrophy. Rhoades W; Dickson D; Do DV Clin Ophthalmol; 2015; 9():1049-56. PubMed ID: 26089637 [TBL] [Abstract][Full Text] [Related]
55. Gift of Sight: Stem-Cell Patches for Wet and Dry Macular Degeneration. Mertz L IEEE Pulse; 2019; 10(2):8-13. PubMed ID: 31021751 [TBL] [Abstract][Full Text] [Related]
56. Letter to the editor. Eichenbaum DA Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):301. PubMed ID: 25835306 [No Abstract] [Full Text] [Related]
57. Additional Information About Pegcetacoplan for Treatment of Geographic Atrophy Growth. Bressler NM JAMA Ophthalmol; 2024 Feb; 142(2):86. PubMed ID: 38358447 [No Abstract] [Full Text] [Related]
58. To Treat or Not to Treat Geographic Atrophy - That is the Question. Del Priore LV Ophthalmol Retina; 2024 Mar; 8(3):207-209. PubMed ID: 38448115 [No Abstract] [Full Text] [Related]
59. Clinical trial results often overstate benefits of treatment. Day M BMJ; 2007 Jun; 334(7608):1341. PubMed ID: 17599997 [No Abstract] [Full Text] [Related]
60. Update on current and future novel therapies for dry age-related macular degeneration. Leung E; Landa G Expert Rev Clin Pharmacol; 2013 Sep; 6(5):565-79. PubMed ID: 23971874 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]